PT-141 (Bremelanotide)
Melanocortin receptor agonist for sexual dysfunction
Overview
PT-141 (Bremelanotide) is an FDA-approved melanocortin receptor agonist for treating hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike PDE5 inhibitors, it works through the central nervous system to increase sexual desire.
Mechanism of Action
Activates melanocortin-4 receptors (MC4R) in the brain → modulates dopaminergic pathways → increases sexual desire centrally → works independently of vascular effects → affects both arousal and desire.
Benefits
- FDA-approved for HSDD
- Works via central nervous system
- Effective in both men and women
- Does not require blood flow
- On-demand dosing
Dosing Protocol
Half-Life
~2.7 hours
Duration of pharmacological activity after administration.
Side Effects
- Nausea (most common, 40%)
- Flushing
- Headache
- Nasal congestion
- Transient blood pressure increase
- Skin hyperpigmentation
Stacking Recommendations
Storage & Reconstitution
Lyophilized: 2–8°C. Reconstituted: 2–8°C, use within 14 days.
Research Notes
FDA-approved as Vyleesi (2019) for HSDD in premenopausal women. Originally developed from melanotan. Unique mechanism compared to PDE5 inhibitors. Studies show efficacy in both sexes.
Medical Disclaimer
This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment recommendations. Peptide therapy should only be initiated under the supervision of a qualified healthcare provider. Individual results may vary. Always consult with your physician before starting any new therapy. Regulatory status varies by jurisdiction.